<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599414</url>
  </required_header>
  <id_info>
    <org_study_id>P02262</org_study_id>
    <nct_id>NCT03599414</nct_id>
  </id_info>
  <brief_title>CASPA: CArdiac Sarcoidosis in PApworth</brief_title>
  <acronym>CASPA</acronym>
  <official_title>CASPA (CArdiac Sarcoidosis in PApworth): Improving the Diagnosis of Cardiac Disease in Patients With Pulmonary Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Papworth Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcoidosis is a disease of unknown cause which affects adults of all ethnic backgrounds.&#xD;
      Clumps of tissue called granulomas develop primarily in the lungs, but can damage other&#xD;
      organs, especially the heart. Anecdotal evidence from autopsy studies suggests the heart is&#xD;
      affected in up to 68% of patients, but there is much uncertainty about this figure.&#xD;
&#xD;
      If undetected and untreated, it can lead to serious complications or even sudden death. The&#xD;
      current recommendation is to perform heart tracings (ECG s) on all patients, but this detects&#xD;
      fewer than half of those with heart involvement.&#xD;
&#xD;
      Blood markers traditionally used to diagnose heart disease are unreliable, meaning there is&#xD;
      no simple blood test in use.&#xD;
&#xD;
      The investigators propose a study with three aims. Firstly, identify the true prevalence of&#xD;
      heart disease by performing Magnetic Resonance Imaging (MRI) scans on a group of patients&#xD;
      with newly diagnosed lung sarcoidosis. Those found to have heart disease will have specialist&#xD;
      (but routine) electrical heart tests. Secondly, (and perhaps the most immediate and&#xD;
      clinically relevant) to identify the best method of diagnosing heart involvement using a&#xD;
      combination of three simple tests: advanced ECG, 24-hour continuous ECG and a new type of&#xD;
      computerised ultrasound scan. Thirdly, to identify proteins in the blood that could be used&#xD;
      to develop a simple blood test for heart involvement in patients with lung sarcoidosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of cardiac sarcoidosis in patients with pulmonary sarcoidosis</measure>
    <time_frame>on Day 1</time_frame>
    <description>The prevalence of cardiac sarcoidosis in patients with pulmonary sarcoidosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine and Proteomic profiling</measure>
    <time_frame>after 1 year</time_frame>
    <description>Completion of cytokine and proteomic profiling of patients with pulmonary sarcoidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of cardiac sarcoidosis</measure>
    <time_frame>on Day 1</time_frame>
    <description>Diagnosis of cardiac sarcoidosis by combining signal averaged ECG, speckle tracking echocardiography and 24 hour holter monitoring</description>
  </secondary_outcome>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Pulmonary Sarcoidosis</condition>
  <condition>Cardiac Sarcoidosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of pulmonary sarcoidosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly referred adult patients with pulmonary sarcoidosis and diagnosis made at&#xD;
             multidisciplinary meeting as per current joint BTS/ATS guidance&#xD;
&#xD;
          -  Patient may be on ≤10mg prednisolone at time of recruitment (if already started at&#xD;
             another site prior to referral).&#xD;
&#xD;
          -  Able to give informed consent and able to comply with protocol&#xD;
&#xD;
          -  ≥&gt;18 yrs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other cardiac disease (e.g. coronary artery disease)cardiac surgery or&#xD;
             previous myocardial infarction (MI)&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  &lt;18 yrs&#xD;
&#xD;
          -  Patient may be on &gt;10mg prednisolone at time of recruitment (if already started at&#xD;
             another site prior to referral).&#xD;
&#xD;
          -  On non-steroidal medication including methotrexate&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Alcoholism&#xD;
&#xD;
          -  Illicit drug abuse&#xD;
&#xD;
        Exclusion criteria for MRI:&#xD;
&#xD;
          -  Cardiac pacemakers&#xD;
&#xD;
          -  Surgical clips in the head (particularly aneurysm clips)&#xD;
&#xD;
          -  Electronic inner ear implants (bionic ears)&#xD;
&#xD;
          -  Ocular metal fragments • Electronic stimulators • Implanted pumps&#xD;
&#xD;
          -  Severe claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhunthan Thillai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Papworth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhunthan Thillai</last_name>
    <phone>01480366359</phone>
    <email>muhunthan.thillai@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Stoneman</last_name>
    <phone>01223639865</phone>
    <email>victoria.stoneman@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Papworth Hospital</name>
      <address>
        <city>Papworth Everard</city>
        <state>Cambridgeshire</state>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Stoneman, PhD</last_name>
      <phone>01223639865</phone>
      <email>victoria.stoneman@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Gray</last_name>
      <phone>01223639717</phone>
      <email>jennifer.gray13@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>cardiac</keyword>
  <keyword>MRI</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>pulmonary</keyword>
  <keyword>cytokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

